Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial

Circulation

Volumn 108, Issue 10, 2003, Pages 1184-1190

  Granger, Christopher B ^a   Mahaffey, Kenneth W ^a   Weaver, W Douglas ^b   Theroux, Pierre ^c   Hochman, Juith S ^d   Filloon, Thomas G ^e   Rollins, Scott ^f   Todaro, Thomas G ^e   Nicolau, Jose C ^g   Ruzyllo, Witold ^h   Armstrong, Paul W ⁱ  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c MONTREAL HEART INSTITUTE   (Canada)

^d Columbia University ^*  (United States)

^e PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^f ALEXION PHARMACEUTICALS   (United States)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

^h INSTITUTE OF CARDIOLOGY   (Poland)

ⁱ UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Angioplasty; Inflammation; Myocardial infarction; Reperfusion

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; COMPLEMENT COMPONENT C5; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; MONOCLONAL ANTIBODY; PEXELIZUMAB; PLACEBO; STATINE; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADJUVANT THERAPY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BOLUS INJECTION; CARDIOGENIC SHOCK; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; ELECTROCARDIOGRAM; FEMALE; HEART FAILURE; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART RUPTURE; HUMAN; INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; ST SEGMENT ELEVATION; STROKE; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; CHEMOTHERAPY, ADJUVANT; COMPLEMENT C5; CREATINE KINASE; CREATINE KINASE, MB FORM; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0042917638     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000087447.12918.85     Document Type: Article

References (28)

1. Langlois PF, Gawryl MS. Detection of the terminal complement complex in patient plasma following acute myocardial infarction. Atherosclerosis. 1988;70:95-105.
2. Griselli M, Herbert J, Hutchinson WL, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med. 1999;190:1733-1740.
3. Lagrand WK, Niessen HW, Wolbink GJ, et al. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation. 1997;95:97-103.
4. Barrett TD, Hennan JK, Marks RM, et al. C-reactive-protein-associated increase in myocardial infarct size after ischemia/reperfusion. J Pharmacol Exp Ther. 2002;303:1007-1013.
5. Beranek JT. C-reactive protein and complement in myocardial infarction and postinfarction heart failure. Eur Heart J. 1997;18:1834-1836.
6. Mathey D, Schofer J, Schafer HJ, et al. Early accumulation of the terminal complement-complex in the ischaemic myocardium after reperfusion. Eur Heart J. 1994;15:418-423.
7. Vakeva AP, Agah A, Rollins SA, et al. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation. 1998;97:2259-2267.
8. Mahaffey KW, Granger CB, Nicolau JC, et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation. 2003;108:1176-1183.
9. Vollmer RT, Christenson RH, Reimer K. et al. Temporal creatine kinase curves in acute myocardial infarction: implications of a good empiric fit with the log-normal function. Am J Clin Pathol. 1993;100:293-298.
10. Rinder CS, Rinder HM, Smith BR, et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest. 1995;96:1564-1572.
11. Stahl GL, Amsterdam EA, Symons JD, et al. Role of thromboxane A2 in the cardiovascular response to intracoronary C5a. Circ Res. 1990;66:1103-1111.
12. Topham PS, Haydar SA, Kuphal R, et al. Complement-mediated injury reversibly disrupts glomerular epithelial cell actin microfilaments and focal adhesions. Kidney Int. 1999;55:1763-1775.
13. Torbohm I, Schonermark M, Wingen AM, et al. C5b-8 and C5b-9 modulate the collagen release of human glomerular epithelial cells. Kidney Int. 1990;37:1098-2004.
14. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002;53:31-47.
15. Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation. 2003;107:2998-3002.
16. Anzai T, Yoshikawa T, Shiraki H, et al. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation. 1997;96:778-784.
17. Lindmark E, Diderholm E, Wallentin L, et al. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA. 2001;286:2107-2113.
18. Liuzzo G, Buffon A, Biasucci LM, et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation. 1998;98:2370-2376.
19. Buerke M, Murohara T, Lefer AM. Cardioprotective effects of a Cl esterase inhibitor in myocardial ischemia and reperfusion. Circulation. 1995;91:393-402.
20. Amsterdam EA, Stahl GL, Pan HL, et al. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol. 1995;268:H448-H457.
21. de Zwaan C, Kleine AH, Diris JH, et al. Continuous 48-h Cl-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J. 2002;23:1670-1677.
22. Vikevä A, Morgan BP, Tikkanen I, et al. Time course of complement activation and inhibitor expression after ischemic injury of rat myocardium. Am J Pathol. 1994;144:1357-1368.
23. Saraste A, Pulkki K, Kallajoki M, et al. Apoptosis in human acute myocardial infarction. Circulation. 1997;95:320-323.
24. Cotter G, Kaluski E, Blatt A, et al. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation. 2000;101:1358-1361.
25. Krucoff MW, Croll MA, Pope JE, et al. Continuous 12-lead ST-segment recovery analysis in the TAMI 7 study. Circulation. 1993;88:137-446.
26. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation. 2000;101:570-580.
27. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein Ilb/IIIa integrin in ischemic heart disease. Circulation. 1998;98:2829-2835.
28. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition. Lancet. 2001;357:1905-1914.